EnBiotix: Funding, Investors & Team (Oct 2026)
EnBiotix is a product-focused bioengineering company that advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with the potential to significantly impact the lives of patients, caregivers, and payors worldwide. It was founded in 2012 and is headquartered in Cambridge, Massachusetts.
EnBiotix has raised $14.5M across 2 funding rounds on record, the most recent an undisclosed round of $3.5M announced in Apr 2022.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
EnBiotix Company Profile and Key Stats
Latest funding round on record: Apr 2022.
EnBiotix Funding Rounds
EnBiotix raised $11.0M in a Convertible Note announced in Dec 2021.
4 months later, an undisclosed round of $3.5M was announced in Apr 2022.
EnBiotix Founders and Leadership Team
No contact details are on record for this team yet.
EnBiotix Funding Compared to Other Biotechnology Startups
EnBiotix's latest round of $3.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like EnBiotix in Biotechnology and Cambridge
Companies Similar to EnBiotix
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
EnBiotix Funding FAQs
What does EnBiotix do?
EnBiotix is a product-focused bioengineering company that advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with the potential to significantly impact the lives of patients, caregivers, and payors worldwide. It was founded in 2012 and is headquartered in Cambridge, Massachusetts.
How much funding has EnBiotix raised?
EnBiotix has raised $14.5M across 2 rounds on record. The most recent is an undisclosed round of $3.5M announced in Apr 2022.
When did EnBiotix last raise funding?
EnBiotix's most recent funding round on record is an undisclosed round of $3.5M, announced in Apr 2022.
Who is the CEO of EnBiotix?
Jeffrey Wager is listed as CEO at EnBiotix.
Where is EnBiotix headquartered?
EnBiotix is based in Cambridge, Massachusetts, United States.
How many employees does EnBiotix have?
EnBiotix is in the 1-10 employee band.
How does EnBiotix's funding compare to other Biotechnology startups?
EnBiotix's latest round of $3.5M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's EnBiotix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for EnBiotix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.